5.725USD-2.64%Mkt Cap: 68.27M USDP/E: —Last update: 2026-05-26
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical and proton cancer therapy company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. I…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap68.27M USD
Enterprise Value58.91M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-6.01M USD
Revenue/Share—
Last Price5.725 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees3
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B6.55
EPS (TTM)-1.15
EPS (Forward)—
52W Range
0.640090% of range6.260
52W High6.260 USD
52W Low0.6400 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-62.18%
ROA-47.19%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.07M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-1.87%
Net Debt-4.07M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.07
Current Ratio3.88
Quick Ratio3.83
Book Value/Sh0.9020 USD
Cash/Share0.4400 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateNov 20, 2020
Splits
Last Split1:10
Split DateJun 5, 2023
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.12.38M
Float11.11M
Insiders4.47%
Institutions6.89%
Short Interest
Short Ratio0.7d
Short % Float0.21%
Short % Out.0.21%
Shares Short24.41K
Short (prev mo.)49.93K
Technical
SMA 503.666 (+56.1%)
SMA 2003.949 (+45.0%)
Beta1.05
S&P 52W Chg28.31%
Avg Vol (30d)69.28K
Avg Vol (10d)95.17K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—